These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9333150)

  • 1. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
    Pilgrim AK; Pantaleo G; Cohen OJ; Fink LM; Zhou JY; Zhou JT; Bolognesi DP; Fauci AS; Montefiori DC
    J Infect Dis; 1997 Oct; 176(4):924-32. PubMed ID: 9333150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.
    Forthal DN; Landucci G; Daar ES
    J Virol; 2001 Aug; 75(15):6953-61. PubMed ID: 11435575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
    Montefiori DC; Pantaleo G; Fink LM; Zhou JT; Zhou JY; Bilska M; Miralles GD; Fauci AS
    J Infect Dis; 1996 Jan; 173(1):60-7. PubMed ID: 8537683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection.
    Carotenuto P; Looij D; Keldermans L; de Wolf F; Goudsmit J
    AIDS; 1998 Sep; 12(13):1591-600. PubMed ID: 9764777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.
    Sarmati L; d'Ettorre G; Nicastri E; Ercoli L; Uccella I; Massetti P; Parisi SG; Vullo V; Andreoni M
    Clin Diagn Lab Immunol; 2001 Jul; 8(4):822-4. PubMed ID: 11427434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
    Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
    J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
    Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC
    J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
    Deeks SG; Schweighardt B; Wrin T; Galovich J; Hoh R; Sinclair E; Hunt P; McCune JM; Martin JN; Petropoulos CJ; Hecht FM
    J Virol; 2006 Jun; 80(12):6155-64. PubMed ID: 16731954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
    Rodriguez SK; Sarr AD; MacNeil A; Thakore-Meloni S; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Virol; 2007 May; 81(10):5331-8. PubMed ID: 17301136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.
    Harrer T; Harrer E; Kalams SA; Elbeik T; Staprans SI; Feinberg MB; Cao Y; Ho DD; Yilma T; Caliendo AM; Johnson RP; Buchbinder SP; Walker BD
    AIDS Res Hum Retroviruses; 1996 May; 12(7):585-92. PubMed ID: 8743084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity.
    Pernas M; Sanchez-Merino V; Casado C; Merino-Mansilla A; Olivares I; Yuste E; Lopez-Galindez C
    PLoS One; 2015; 10(8):e0134054. PubMed ID: 26258485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS
    J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals.
    von Gegerfelt A; Chiodi F; Keys B; Norkrans G; Hagberg L; Fenyö EM; Broliden K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1133-8. PubMed ID: 1503825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.